QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
NASDAQ:SPRO

Spero Therapeutics (SPRO) Stock Forecast, Price & News

$1.80
+0.03 (+1.69%)
(As of 06/6/2023 ET)
Compare
Today's Range
$1.77
$1.82
50-Day Range
$1.44
$1.95
52-Week Range
$0.68
$3.18
Volume
112,803 shs
Average Volume
466,847 shs
Market Capitalization
$94.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

Spero Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
288.9% Upside
$7.00 Price Target
Short Interest
Healthy
1.85% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.80
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.05) to ($1.00) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

297th out of 981 stocks

Pharmaceutical Preparations Industry

137th out of 464 stocks


SPRO stock logo

About Spero Therapeutics (NASDAQ:SPRO) Stock

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.

Receive SPRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SPRO Stock News Headlines

WARNING TO ALL U.S. INVESTORS
May 16, 2023... The Day That Will Financially Paralyze 181 Million American Investors... Here are 3 steps to prepare yourself >>>
Q1 2023 Spero Therapeutics Inc Earnings Call
Spero Therapeutics Q1 2023 Earnings Preview
WARNING TO ALL U.S. INVESTORS
May 16, 2023... The Day That Will Financially Paralyze 181 Million American Investors... Here are 3 steps to prepare yourself >>>
Spero Therapeutics's Earnings: A Preview
Here's what Wall Street expects from Spero Therapeutics's earnings
See More Headlines

SPRO Price History

SPRO Company Calendar

Last Earnings
3/30/2023
Today
6/06/2023
Next Earnings (Estimated)
8/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SPRO
Fax
N/A
Employees
146
Year Founded
2013

Price Target and Rating

Average Stock Price Forecast
$7.00
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+288.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-46,420,000.00
Pretax Margin
-50.18%

Debt

Sales & Book Value

Annual Sales
$53.51 million
Book Value
$1.45 per share

Miscellaneous

Free Float
50,280,000
Market Cap
$94.63 million
Optionable
Optionable
Beta
0.89

Social Links


Key Executives

  • Ankit A. MahadeviaAnkit A. Mahadevia
    President, Chief Executive Officer & Director
  • Timothy Keutzer
    Chief Operating Officer
  • Satyavrat Shukla
    Chief Financial Officer & Treasurer
  • Kamal Hamed
    Chief Medical Officer
  • Angela Talley
    Senior Vice President-Clinical Development













SPRO Stock - Frequently Asked Questions

Should I buy or sell Spero Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SPRO shares.
View SPRO analyst ratings
or view top-rated stocks.

What is Spero Therapeutics' stock price forecast for 2023?

3 equities research analysts have issued 12-month target prices for Spero Therapeutics' shares. Their SPRO share price forecasts range from $6.00 to $8.00. On average, they anticipate the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 288.9% from the stock's current price.
View analysts price targets for SPRO
or view top-rated stocks among Wall Street analysts.

How have SPRO shares performed in 2023?

Spero Therapeutics' stock was trading at $1.73 at the beginning of 2023. Since then, SPRO stock has increased by 4.0% and is now trading at $1.80.
View the best growth stocks for 2023 here
.

Are investors shorting Spero Therapeutics?

Spero Therapeutics saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 974,400 shares, a drop of 32.8% from the April 30th total of 1,450,000 shares. Based on an average daily trading volume, of 573,600 shares, the short-interest ratio is presently 1.7 days.
View Spero Therapeutics' Short Interest
.

When is Spero Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our SPRO earnings forecast
.

How were Spero Therapeutics' earnings last quarter?

Spero Therapeutics, Inc. (NASDAQ:SPRO) issued its quarterly earnings results on Thursday, March, 30th. The company reported $0.55 earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.95. The firm had revenue of $47.44 million for the quarter, compared to analyst estimates of $1.60 million. Spero Therapeutics had a negative net margin of 50.18% and a negative trailing twelve-month return on equity of 51.35%.

What ETFs hold Spero Therapeutics' stock?

ETFs with the largest weight of Spero Therapeutics (NASDAQ:SPRO) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS).

What is Ankit Mahadevia, MD's approval rating as Spero Therapeutics' CEO?

27 employees have rated Spero Therapeutics Chief Executive Officer Ankit Mahadevia, MD on Glassdoor.com. Ankit Mahadevia, MD has an approval rating of 100% among the company's employees. This puts Ankit Mahadevia, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Spero Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spero Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Editas Medicine (EDIT), SCYNEXIS (SCYX), Kadmon (KDMN), Aldeyra Therapeutics (ALDX), KushCo (KSHB), Dynavax Technologies (DVAX) and Zosano Pharma (ZSAN).

When did Spero Therapeutics IPO?

(SPRO) raised $75 million in an IPO on Thursday, November 2nd 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

What is Spero Therapeutics' stock symbol?

Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO."

Who are Spero Therapeutics' major shareholders?

Spero Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Anson Funds Management LP (6.36%), Renaissance Technologies LLC (0.78%), Geode Capital Management LLC (0.64%), XTX Topco Ltd (0.23%), Group One Trading L.P. (0.00%) and Two Sigma Investments LP (0.06%). Insiders that own company stock include Ankit Mahadevia, Aquilo Capital Management, Llc, Cristina Larkin, Sath Shukla and Timothy Keutzer.
View institutional ownership trends
.

How do I buy shares of Spero Therapeutics?

Shares of SPRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Spero Therapeutics' stock price today?

One share of SPRO stock can currently be purchased for approximately $1.80.

How much money does Spero Therapeutics make?

Spero Therapeutics (NASDAQ:SPRO) has a market capitalization of $94.63 million and generates $53.51 million in revenue each year. The company earns $-46,420,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis.

How many employees does Spero Therapeutics have?

The company employs 146 workers across the globe.

How can I contact Spero Therapeutics?

Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The official website for the company is sperotherapeutics.com. The company can be reached via phone at (857) 242-1600 or via email at ir@sperotherapeutics.com.

This page (NASDAQ:SPRO) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -